Non-invasive ventilation for very old patients with limitations to respiratory care in half-open geriatric ward: experience on a consecutive cohort of patients

2014 ◽  
Vol 26 (6) ◽  
pp. 615-623 ◽  
Author(s):  
Nicola Vargas ◽  
Maria Vargas ◽  
Vincenzo Galluccio ◽  
Saverio Carifi ◽  
Carmen Villani ◽  
...  
2019 ◽  
Vol 36 (5) ◽  
pp. 303-305 ◽  
Author(s):  
Gaetano Montoneri ◽  
Paola Noto ◽  
Francesca Maria Trovato ◽  
Giuseppe Mangano ◽  
Lorenzo Malatino ◽  
...  

BackgroundNon-invasive ventilation (NIV) is increasingly used to support very old (aged ≥85 years) patients with acute respiratory failure (ARF). This retrospective observational study evaluated the impact of NIV on the prognosis of very old patients who have been admitted to the intermediate care unit (IMC) of the Emergency Department of the University Hospital Policlinico-Vittorio Emanuele of Catania for ARF.MethodsAll patients admitted to the IMC between January and December 2015 who received NIV as the treatment for respiratory failure were included in this study. Outcomes of patients aged ≥85 years were compared with lower ages. The expected intrahospital mortality was calculated through the Simplified Acute Physiology Score (SAPS) II and compared with the observed mortality.ResultsThe mean age was 87.9±2.9 years; the M:F ratio was approximately 1:3. The average SAPS II was 50.1±13.7. The NIV failure rate was 21.7%. The mortality in the very old group was not statistically different from the younger group (20% vs 25.6%; d=5.6%; 95% CI −8% to 19%; p=0.404). The observed mortality was significantly lower than the expected mortality in both the group ≥85 (20.0% vs 43.4%, difference=23.4%; 95% CI 5.6% to 41.1%, p=0.006) and the younger group (25.6% vs 38.5%, difference=12.9%; 95% CI −0.03% to 25.8%, p=0.046). In both age groups, patients treated with NIV for chronic obstructive pulmonary disease had lower mortalities than those treated for other illnesses, although this was statistically significant only in the younger group.ConclusionIn very old patients, when used with correct indications, NIV was associated with mortality similar to younger patients. Patients receiving NIV had lower than expected mortality in all age groups.


2019 ◽  
Vol 36 (8) ◽  
pp. 514.2-515
Author(s):  
Francesca Maria Trovato ◽  
Gaetano Montoneri ◽  
Paola Noto ◽  
Giuseppe Mangano ◽  
Giuseppe Carpinteri ◽  
...  

Author(s):  
Leonor Furtado Almeida Cunha ◽  
Maria Jacob ◽  
Mafalda Van Zeller ◽  
Tiago Pinto ◽  
Miguel Gonçalves ◽  
...  

Author(s):  
Siddhartha Modak ◽  
Sumit Roy Tapadar ◽  
Mita Saha Dutta Chowdhury ◽  
Arunabha Datta Chaudhuri

Introduction: Patients with Acute Respiratory Failure (ARF) can be ventilated noninvasively through Bi-Level Positive Pressure Ventilation (Bi-PAP). The proper timing, indications and outcome of Non-invasive Ventilation (NIV) have been evaluated worldwide by many investigators. Optimum selection of patients leads to better outcome reducing need for invasive ventilation; while the reverse can cause inappropriate delay in intubation leading to clinical deterioration, increased morbidity and mortality. Aim: To evaluate the indications and outcome, with relevant factors in all patients requiring NIV in Respiratory Care Unit (RCU) of a teaching hospital. Materials and Methods: This was a hospital-based observational study conducted from April 2016 to March 2017. After ethical approval, all patients who were put on NIV in RCU of the institution during the period of one year were enlisted. Evaluation by history, detailed clinical examination and necessary investigations including blood count, biochemistry, Arterial Blood Gas (ABG) analysis, oxymetry, microbiological investigations, imaging of thorax etc., was done. Examination and investigations were periodically repeated as necessary. Pre-fixed NIV protocol and end point definitions were followed. Descriptive statistics done using Mean and Standard Deviation (SD). Mann-Whitney U test was done for comparing quantitative data. Chi-square test or Fisher’s-exact test was used to compare categorical data. Results: Most common age group for Respiratory Failure (RF) was 41 to 60 years, (mean 56.5±11.6), with a male predominance (M:F=1.4:1). The most common underlying disease leading to RF and requiring NIV support was Acute Exacerbation of Chronic Obstructive Pulmonary Disorder (COPD) (n=31) in Type 2 and pneumonia (n=11) in Type 1 RF. Hypertension (25%) and diabetes mellitus (20%) were common co-morbidities. Favourable outcome was seen in 68.33% patients an average hospital stay of 15 days. The baseline APACHE-II (Acute Physiology and Chronic Health Evaluation) score (p≤0.0001) and Partial Pressure of Oxygen(PaO2)/ Fraction of Inspired Oxygen (FiO2) at 1st hour of NIV (p=0.0054) have significant predictive value the outcome. Reasons for shifting to IMV were: non-improvement of ABG (37.93%), worsening of dyspnoea (24.14%) and haemodynamic instability (20.7%). Average time gap from initiation of NIV to mechanical ventilation in failure cases was 8.03 hours in Type 2 RF and 5.78 hours in Type 1 RF. Fatality rate in Type 2 RF (23.68%) was much less than in Type 1 RF (45.45%). Conclusion: This study strengthens the fact that efficient utilisation of NIV therapy in properly selected patients of acute RF can lead to reduced need for IMV, thus reducing the cost and complications. Disease severity at admission (APACHE-II score), non-improvement of ABG parameters in 1st and 4th hour of NIV initiation, PaO2/FiO2 ratio, development of haemodynamic instability and deteriorating level of consciousness, all play pivotal roles in the outcome assessment.


2021 ◽  
Vol 12 (2) ◽  
pp. 63-67
Author(s):  
P. Kremeier

The COVID-19 pandemic confronts intensive care medicine with a new clinical picture, which is manifested in various forms and which clearly differs from the classic acute respiratory distress syndrome (ARDS). Ventilation therapy for COVID-19 pneumonia is complex and, contrary to previous guidelines for the treatment of acute respiratory failure, an increasing number of these patients do not primarily receive invasive ventilation. High-flow O2 therapy and non-invasive ventilation by mask or ventilation helmet have become key treatment options. In endeavours to provide respiratory care to all segments of the population whenever necessary, other therapeutic devices may be employed. The fact that milder cases of these diseases can also be treated with less expensive out-of-hospital ventilators and HFOT devices and that a full-fledged intensive care ventilator may not be imperative must be considered in the final decision. Nevertheless, answers to the triage and allocation of ventilators must be found in a discussion involving society as a whole and the health sciences in particular. The health sciences are called upon to contribute to the public debate on the distribution of all necessary resources during the pandemic.


Sign in / Sign up

Export Citation Format

Share Document